Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride

Patra, Chinam Niranjan; Kumar, Arethi Bharani; Pandit, Hemant Kumar; Singh, Satya Prakash; Devi, M. Vimala

doi:10.2478/v10007-007-0038-0

Cited by 63 publications

(49 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DLTs were prepared by direct compression using a single-punch tableting machine where its die was initially filled with the weighed amount of sustained-release portion and lightly compressed, then the fast-release portion was added directly onto the obtained compressed tablet, and then recompressed together to combine them (7,8). The total weight of each DLT was adjusted to 200 mg containing 8 mg of lornoxicam fractioned between the two layers.…”

Section: Formulation Of Lornoxicam Dltsmentioning

confidence: 99%

“…Such a tablet is considered as a biphasic delivery system that is designed to release the drug at two different rates and is usually composed of a fast-release layer combined with single (7)(8)(9)(10) or double sustained-release layers (11,12). Generally, conventional controlled-release dosage forms delay the release of drugs and do not provide a rapid onset of action after oral administration (13,14).…”

Section: Introductionmentioning

confidence: 99%

“…The layered tablet concept has been utilized to develop controlled-release formulations (7)(8)(9)(10)(11)(12). Such a tablet is considered as a biphasic delivery system that is designed to release the drug at two different rates and is usually composed of a fast-release layer combined with single (7)(8)(9)(10) or double sustained-release layers (11,12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Design and In Vitro Evaluation of Novel Sustained-Release Double-Layer Tablets of Lornoxicam: Utility of Cyclodextrin and Xanthan Gum Combination

Hamza

Aburahma

2009

AAPS PharmSciTech

View full text Add to dashboard Cite

Abstract. The objective of the present study was to develop new directly compressed, double-layer tablets (DLTs) of lornoxicam, a highly potent nonsteroidal anti-inflammatory drug with short half-life, that are characterized by initial burst drug release in the stomach and comply with the release requirements of sustained-release products. Each of the proposed DLTs is composed of a fast-release layer and a sustained-release layer, anticipating rapid drug release that starts in the stomach to rapidly alleviate the symptoms and continues in the intestine to maintain protracted analgesic effect. An amorphous, freeze-dried inclusion complex of lornoxicam with hydroxypropyl-β-cyclodextrin, present in 1:2 (drug/cyclodextrin) molar ratio, was employed in the fast-release layer to enhance the dissolution of lornoxicam in the stomach and assure rapid onset of its analgesic effect. Xanthan gum (XG), a hydrophilic matrix-forming agent, was integrated in the sustained-release layer to provide appropriate sustainment of drug release. The weight ratios between the sustained-release layer and fast-release layer present in DLTs were adjusted to reach optimal formulations. DLTs composed of sustained-release layer (40% XG) to fast-release layer in 2:1 weight ratio and those composed of sustained-release layer (50% XG) to fast-release layer in 1:1 weight ratio showed the desired release profile. The drug contained in the fast-release layer showed an initial burst drug release of more than 30% of its drug content during the first 30 min of the release study followed by gradual release of the drug for a period of 8 h.

show abstract

Section: Formulation Of Lornoxicam Dltsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design and In Vitro Evaluation of Novel Sustained-Release Double-Layer Tablets of Lornoxicam: Utility of Cyclodextrin and Xanthan Gum Combination

Hamza

Aburahma

2009

AAPS PharmSciTech

View full text Add to dashboard Cite

show abstract

“…The flask was shaken for 10 min. Finally, the volume was made up to the mark with phosphate buffer pH 4.5 (13). The mixture was then filtered and 1 mL of the filtrate was suitably diluted with phosphate buffer pH 4.5 to obtain a solution containing about 30 mg mL -1 of metoclopramide hydrochloride and analyzed for metoclopramide hydrochloride content at 272 nm using a Systronic 2201 double beam UV/Visible spectrophotometer (Shimadzu 1700 UV-Visible Spectrophotometer, Japan) and phosphate buffer pH 4.5 as blank.…”

Section: Preparation and Characterization Of Dual Component Vaginal Tmentioning

confidence: 99%

Compressed matrix dual-component vaginal drug delivery system containing metoclopramide hydrochloride

Patel¹,

Patel²

2009

Acta Pharmaceutica

View full text Add to dashboard Cite

The vagina, as a drug delivery site, offers certain unique features that can be exploited in order to achieve desirable therapeutic effects. By contrast, scientific knowledge of the possibilities of drug delivery via the vagina is limited. The currently available vaginal dosage forms have limitations, such as leakage, messiness and low residence time, which contribute to poor subject or patient compliance (1).In general, conventional controlled dosage forms delay the release of therapeutic systemic levels and do not provide a rapid onset of action. To modify the release of the drug from these systems, the surface area exposed to a fluid can be restricted by the addition of barrier layers to one or both sides of the tablets (2-4). However, most multilayer sys- The purpose of the present investigation was to produce a quick/slow biphasic delivery system for metoclopramide hydrochloride using the superdisintegrant Ac-di-sol for the fast release layer and hydroxypropyl methylcellulose K100M and Ucarflock 302 to modulate the release of the drug. A dual component tablet made up of a sustained release and an immediate release layer was prepared by direct compression. A 3 2 full factorial design was applied to systematically optimize the drug release profile of the sustained release layer. The results of the full factorial design indicate that a small amount of HPMC K100M and a large amount of Ucarflock 302 favor sustained release of the metoclopramide hydrochloride vaginal dual component system. The ex vivo residence time reveals that the formulation was retained for more than 10 h. The formulation gave an initial burst effect to provide the loading dose of the drug followed by sustained release for 12 h, thus solving the problem of repeated administration, especially in pregnancy.

show abstract

“…For such highly water soluble drugs, it becomes necessary to incorporate another type of polymer in the matrix system. Among such polymers, Eudragit RLPO or RSPO have been used successfully to formulate appropriate sustained release matrix formulations [12][13][14]. The aim of the present study, therefore, was to design a sustained release matrix tablet capable of producing 20 -24 h sustained release of diltiazem HCl using a combination of hydrophobic and gelling hydrophilic polymer.…”

Section: Introductionmentioning

confidence: 99%

Formulation and <i>In vitro/In vivo</i> Evaluation of Sustained Release Diltiazem Matrix Tablets

Baviskar¹,

Sharma²,

Jain³

2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride

Cited by 63 publications

References 15 publications

Design and In Vitro Evaluation of Novel Sustained-Release Double-Layer Tablets of Lornoxicam: Utility of Cyclodextrin and Xanthan Gum Combination

Design and In Vitro Evaluation of Novel Sustained-Release Double-Layer Tablets of Lornoxicam: Utility of Cyclodextrin and Xanthan Gum Combination

Compressed matrix dual-component vaginal drug delivery system containing metoclopramide hydrochloride

Formulation and <i>In vitro/In vivo</i> Evaluation of Sustained Release Diltiazem Matrix Tablets

Contact Info

Product

Resources

About